



Standard Formulary

Exclusion, Step Therapy and Negative Tiering Changes

Effective: January 1, 2017

Formulary Exclusions

Therapeutic Category	Formulary Exclusion	Formulary Alternative
ANALGESICS		
Nonsteroidal Anti-inflammatory Agents (NSAIDs) <i>New Category</i>	Zipsor	diclofenac potassium, Zorvolex [NP]
Opioid Agonists - Extended Release <i>New Category</i>	Nucynta ER	Belbuca, Butrans, Hysingla ER, Opana ER, Oxycontin, Zohydro ER [NP]
Opioid Agonists - Immediate Release <i>New Category</i>	Nucynta	generic immediate release opioids
ANTI-ADDICTION / SUBSTANCE ABUSE TREATMENT		
Opioid Abuse <i>New Category</i>	Bunavail, buprenorphine/naloxone, Zubsolv	Suboxone Film
ANTIVIRALS		
Hepatitis C	Olysio, Technivie, Viekira, Zepatier	Daklinza, Harvoni, Sovaldi
AUTONOMIC & CENTRAL NERVOUS SYSTEM		
Transmucosal Fentanyl Analgesics <i>New Category</i>	Abstral, Fentora, Lazanda, Subsys	fentanyl lozenge
CONTRACEPTIVES		
Oral Contraceptives	generic Beyaz*, generic Safyral*, generic Yasmin ¹ , generic Yaz ¹	Beyaz, Natazia, Safyral, Yasmin, Yaz
DERMATOLOGY		
Acne (Oral Agents)	Absorica	Amnesteem, Claravis, Myorisan, Zenatane
Actinic Keratosis <i>New Category</i>	Carac, fluorouracil 0.5% cream	Picato [NP], Zyclara [NP], fluorouracil 5% cream, imiquimod 5% cream

*Indicates new formulary exclusion to an existing managed therapeutic category effective January 1, 2017

¹generic Yasmin and Yaz are commonly marketed as Gianvi, Loryna, Ocella, Syeda, Vestura, or Zarah

Formulary Exclusions (continued)

Therapeutic Category	Formulary Exclusion	Formulary Alternative
DIABETES		
Biguanides <i>New Category</i>	Fortamet, Glumetza, generic Glumetza	metformin
Blood Glucose Meters & Test Strips	Ascencia (Breeze, Contour), Roche (Accu-Chek), All other test strips that are not Abbott (Freestyle, Precision) or LifeScan (OneTouch) brand*	Abbott (Freestyle, Precision), LifeScan (OneTouch)
Glucagon-Like Peptide-1 Agonists (GLP-1)	Tanzeum, Trulicity	Bydureon, Byetta, Victoza
Rapid Acting Insulin	Afrezza*, Apidra, Humalog, Humulin	Novolog, Novolin
Sodium-Glucose Co-transporter 2 (SGLT-2) Inhibitor & Combinations <i>New Category</i>	Jardiance, Synjardy	Farxiga, Invokana, Invokamet, Xigduo
ENDOCRINE		
Topical Testosterone Products	Androderm, Axiron, Fortesta, Testim	Androgel 1.62%, generic testosterone
GASTROINTESTINAL		
Anti-Inflammatory/Anti-Ulcer Agents	Duexis, Vimovo	famotidine PLUS ibuprofen or omeprazole PLUS naproxen
UROLOGICAL		
Urinary Antispasmodic <i>New Category</i>	Enablex, Toviaz	Myrbetriq, oxybutynin, tolterodine, trospium, Vesicare [NP]
WEIGHT LOSS		
Weight Loss Agents <i>New Category</i>	Saxenda, Qsymia	Belviq, Contrave

*Indicates new formulary exclusion to an existing managed therapeutic category effective January 1, 2017

Step Therapies

Therapeutic Category	Secondary Treatment	Primary Treatment
AUTONOMIC & CENTRAL NERVOUS SYSTEM		
Antidementia Agents <i>New Category</i>	Namenda XR, Namzaric	donepezil, memantine (immediate release)
Multiple Sclerosis	Aubagio ² , Betaseron, Extavia, Lemtrada, Rebif, Tysabri, Zinbryta	Avonex, Copaxone, Gilenya, Plegridy, Tecfidera
DERMATOLOGY		
Antifungals <i>New Category</i>	Kerydin	Jublia
DIABETES		
Dipeptidyl Peptidase-4 Inhibitors (DPP-4) & Combinations	Kazano*, Kombiglyze*, Nesina*, Oseni*, Onglyza*	Janumet, Januvia, Jentadueto, Tradjenta
ENDOCRINE		
Growth Hormone	Humatrope, Nutropin AQ, Omnitrope, Saizen, Zomacton	Genotropin, Norditropin
GASTROINTESTINAL		
Ulcerative Colitis Agents	Asacol HD, Canasa*, Delzicol, Dipentum*, Giazol*, Pentasa	Apriso, Lialda, balsalazide, sulfasalazine
Irritable Bowel Syndrome & Opioid Induced Constipation Agents <i>New Category</i>	Linzess ³ , Movantik, Relistor	Amitiza
HEMATOLOGICAL		
Erythropoiesis-Stimulating Agents <i>New Category</i>	Aranesp, Epogen, Mircera	Procrit
IMMUNOLOGICAL AGENTS		
Inflammatory Conditions	Actemra, Cimzia, Cosentyx, Kineret, Orencia, Otezla, Simponi, Stelara, Taltz, Xeljanz	Enbrel, Humira
RESPIRATORY		
Selective beta-2-Adrenergic Agonists	Proventil, Xopenex	Proair, Ventolin
UROLOGICAL		
Erectile Dysfunction	Cialis ⁴ , Levitra*, Staxyn, Stendra	Viagra

*Indicates new formulary exclusion to an existing managed therapeutic category effective January 1, 2017

²Requires trial and failure of only one primary treatment

^{3,4}Managed by prior authorization to assess indication

Negative Tiering Changes

Non-Preferred Product	Preferred Alternative
Chantix	bupropion
Fetzima	generic antidepressants
Fosrenol	Renvela
Kombiglyze	Janumet, Jentadueto
Namenda XR	memantine
Namzaric	donepezil, memantine
Onglyza	Januvia, Tradjenta
Tekturna	generic ACE inhibitors, generic ARBs
Tekturna HCT	generic ACE inhibitors, generic ARBs
Vesicare	oxybutynin, tolterodine
Viibryd	generic antidepressants

Non-Preferred Products previously considered Preferred in 2016